What is the appropriate prescription wording (sig) and quantity for sumatriptan 50 mg tablets to be taken pro re nata (PRN), limited to no more than nine doses per month to avoid rebound headaches?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prescription Writing for Sumatriptan 50 mg PRN

Write the prescription as: "Take 1 tablet by mouth at onset of migraine; may repeat once after 2 hours if needed. Maximum 2 tablets per day. Do not use more than 9 days per month. Dispense: #18 tablets."

Sig (Prescription Instructions)

The appropriate sig should read:

  • "Take 1 tablet by mouth at onset of migraine headache. May repeat 1 tablet after 2 hours if headache persists or returns. Maximum 2 tablets in 24 hours. Limit use to no more than 9 days per month to prevent medication overuse headache."

Quantity to Dispense

Dispense #18 tablets (9 days × 2 tablets maximum per day = 18 tablets per month) 1.

This quantity explicitly limits the patient to 9 treatment days per month, which is the critical threshold to prevent medication overuse headache. The FDA-approved maximum daily dose is 200 mg (four 50 mg tablets or two 100 mg tablets), but for practical prescribing to prevent rebound headaches, limiting to 9 days per month with a maximum of 2 doses per day is appropriate 1.

Dosing Rationale

Optimal Dose Selection

  • Sumatriptan 50 mg is the optimal starting dose for most patients, balancing efficacy with tolerability 2, 1
  • The 50 mg and 100 mg doses provide greater effect than 25 mg, but 100 mg may not provide significantly greater benefit than 50 mg while having more adverse events 1, 3
  • The 50 mg dose has similar efficacy to 100 mg but with a lower incidence of adverse events 3

Timing and Redosing

  • Instruct patients to take sumatriptan as early as possible when migraine pain is still mild, which significantly improves pain-free response rates (67% vs 36% at 2 hours when treating mild vs moderate/severe pain) 4
  • If headache persists or returns after initial improvement, a second dose may be taken at least 2 hours after the first dose 1
  • Maximum daily dose is 200 mg in 24 hours 1

Preventing Medication Overuse Headache

Critical Monthly Limit

The 9-day-per-month limit is essential to prevent medication overuse headache (rebound headache). The most recent guideline from the American College of Physicians (2025) specifically states that triptans should be limited to ≥10 days per month to avoid medication overuse headache 5. Using a conservative 9-day limit provides a safety margin.

Patient Counseling Points

Counsel patients on:

  • Medication overuse headache is defined as headache occurring ≥15 days per month for at least 3 months in people with preexisting headache disorder, developing due to overuse of acute medication 5
  • The threshold varies by medication: ≥10 days per month for triptans, ≥15 days per month for NSAIDs 5
  • If migraines occur more frequently than 9 days per month, preventive medications should be considered rather than increasing acute treatment frequency 5

Additional Prescribing Considerations

When to Adjust

  • If 50 mg is inadequate after treating 2-3 headache episodes, consider increasing to 100 mg 2
  • If 50 mg causes intolerable side effects, consider decreasing to 25 mg 1
  • Approximately 40% of patients can be maintained on 25 mg tablets in clinical practice 6

Hepatic Impairment

In patients with mild to moderate hepatic impairment, maximum single dose should not exceed 50 mg 1.

Contraindications to Verify

Before prescribing, ensure patient does not have:

  • Ischemic vascular conditions, vasospastic coronary disease, uncontrolled hypertension, or significant cardiovascular disease 2
  • Use of ergotamine or MAOIs 2
  • Use of another triptan within 24 hours 2
  • Hemiplegic or basilar migraine 2
  • Pregnancy (discuss risks if childbearing potential) 5

Efficacy Expectations

Set realistic expectations:

  • Pain-free at 2 hours: approximately 28% with 50 mg vs 11% with placebo (NNT 6.1) 7
  • Headache relief at 2 hours (moderate/severe to mild/none): approximately 61% with 50 mg vs 27% with placebo 2
  • Sustained pain-free through 24 hours: approximately 1 in 9-10 patients (NNT 9.5) 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.